EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study

Sarah R Vreijling, Brenda W J H Penninx, Josine E Verhoeven, Charlotte E Teunissen, Elena R Blujdea, Aartjan T F Beekman, Femke Lamers, Rick Jansen

Brain, Behavior, and Immunity · 2025-01 · 123 · 876-883

DOI: 10.1016/j.bbi.2024.10.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain, Behavior, and Immunity, 2025-01. Verfasst von Sarah R Vreijling und 7 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, M…. Hauptthemen laut MEDLINE: Antidepressive Agents, Anxiety Disorders, Running, Exercise Therapy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Health Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression. METHODS: Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index. RESULTS: Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes. CONCLUSIONS: This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients. TRIAL REGISTRATION: Trialregister.nl Number of identification: NTR3460.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsAnxiety DisordersRunningExercise TherapyHumansMaleFemaleAdultMiddle AgedDepressionTreatment OutcomeDepressive DisorderEscitalopramInflammationMetabolic Syndrome

Stichwörter der Autor:innen

AntidepressantsDepressionExerciseInflammationMetabolismRunning therapy

Substanzen

Antidepressive AgentsEscitalopram

Autor:innen und Institutionen

  • Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health Program, Amsterdam, the Netherlands. Electronic address:…
  • Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health Program, Amsterdam, the Netherlands; Amsterdam Neuroscien…
  • Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health Program, Amsterdam, the Netherlands; GGZ inGeest Mental H…
  • Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands.
  • Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam Public Health, Mental Health Program, Amsterdam, the Netherlands.

Förderung

  • Netherlands Organisation for Health Research and Development

Zitieren

APA

Vreijling, S. R., Penninx, B. W. J. H., Verhoeven, J. E., Teunissen, C. E., Blujdea, E. R., Beekman, A. T. F., Lamers, F., & Jansen, R. (2025). Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study. Brain, Behavior, and Immunity, 123, 876-883. https://doi.org/10.1016/j.bbi.2024.10.033

Vancouver

Vreijling SR, Penninx BWJH, Verhoeven JE, Teunissen CE, Blujdea ER, Beekman ATF, et al. Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study. Brain, Behavior, and Immunity. 2025;123:876-883. doi:10.1016/j.bbi.2024.10.033

BibTeX
@article{Vreijling2025,
  author = {Vreijling, Sarah R and Penninx, Brenda W J H and Verhoeven, Josine E and Teunissen, Charlotte E and Blujdea, Elena R and Beekman, Aartjan T F and Lamers, Femke and Jansen, Rick},
  title = {Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  volume = {123},
  pages = {876--883},
  doi = {10.1016/j.bbi.2024.10.033}
}
Kostenlos starten →